The Experts below are selected from a list of 99975 Experts worldwide ranked by ideXlab platform
Leslie M. Shaw - One of the best experts on this subject based on the ideXlab platform.
-
international federation of clinical chemistry international association of therapeutic Drug Monitoring and clinical toxicology working group on immunosuppressive Drug Monitoring
Therapeutic Drug Monitoring, 2002Co-Authors: David W Hol, Victo W Armstrong, Andrea Griesmache, Raymond G Morris, Kimberly L Napoli, Leslie M. ShawAbstract:Issues surrounding the measurement and interpretation of immunosuppressive Drug concentrations have been summarized in a number of consensus documents, The Scientific Division of the International Federation of Clinical Chemistry has formed a working group in collaboration with the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. This paper sets out the goals of the working group in light of the developments that have occurred in the field of immunosuppressive Drug Monitoring since the publication of the last consensus documents.
-
International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive Drug Monitoring.
Therapeutic drug monitoring, 2002Co-Authors: David W. Holt, Victo W Armstrong, Raymond G Morris, Kimberly L Napoli, Andrea Griesmacher, Leslie M. ShawAbstract:Issues surrounding the measurement and interpretation of immunosuppressive Drug concentrations have been summarized in a number of consensus documents, The Scientific Division of the International Federation of Clinical Chemistry has formed a working group in collaboration with the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. This paper sets out the goals of the working group in light of the developments that have occurred in the field of immunosuppressive Drug Monitoring since the publication of the last consensus documents.
-
Current opinions on therapeutic Drug Monitoring of immunosuppressive Drugs.
Clinical Therapeutics, 1999Co-Authors: Leslie M. Shaw, David W. Holt, Paul Keown, Raman Venkataramanan, Randall W. YatscoffAbstract:The pharmacokinetics of the immunosuppressive Drugs cyclosporine, tacrolimus, mycophenolate mofetil (MMF), and sirolimus are complex and unpredictable. A narrow therapeutic index unique to each patient, as well as variable absorption, distribution, and elimination, are characteristics of these Drugs. Therapeutic Drug Monitoring plays a key role in helping clinicians maintain blood and plasma levels of immunosuppressive Drugs within their respective therapeutic ranges. Variation in concentrations outside the narrow therapeutic ranges can result in adverse clinical outcomes. Therapeutic Drug Monitoring ensures that concentrations are not too high or too low, thereby reducing the risks of toxicity or rejection, respectively. Therapeutic Monitoring of immunosuppressive Drugs has been based on several choices of assay and biologic fluid (ie, whole blood, plasma) appropriate for a particular Drug. High-performance liquid chromatography (HPLC) remains the gold standard among assay methods used to monitor immunosuppressive Drugs. Although HPLC is the assay of choice for cyclosporine, newer monoclonal assays are suitable as well for routine Monitoring. HPLC is also widely used for therapeutic Drug Monitoring of mycophenolic acid, the active metabolite of MMF, and an immunoassay (used in European centers) has been developed. Therapeutic Drug Monitoring of tacrolimus has been improved with the recent development of assays with greater sensitivity and specificity for tacrolimus than those previously available. No commercial assays are currently available for the therapeutic Monitoring of sirolimus. It is also important to identify a specific pharmacokinetic parameter for each individual Drug, whether it is trough or area under the concentration-time curve, that may be most useful as a tool for optimal therapeutic Drug Monitoring in clinical practice. With an increased understanding of the pharmacokinetics of immunosuppressive Drugs, therapeutic Drug Monitoring guidelines will be more clearly defined to ensure the safe and effective management of transplant recipients.
Raymond G Morris - One of the best experts on this subject based on the ideXlab platform.
-
international federation of clinical chemistry international association of therapeutic Drug Monitoring and clinical toxicology working group on immunosuppressive Drug Monitoring
Therapeutic Drug Monitoring, 2002Co-Authors: David W Hol, Victo W Armstrong, Andrea Griesmache, Raymond G Morris, Kimberly L Napoli, Leslie M. ShawAbstract:Issues surrounding the measurement and interpretation of immunosuppressive Drug concentrations have been summarized in a number of consensus documents, The Scientific Division of the International Federation of Clinical Chemistry has formed a working group in collaboration with the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. This paper sets out the goals of the working group in light of the developments that have occurred in the field of immunosuppressive Drug Monitoring since the publication of the last consensus documents.
-
Therapeutic Drug Monitoring.
Current opinion in anaesthesiology, 2002Co-Authors: Gillian M Shenfield, Raymond G MorrisAbstract:Traditionally, therapeutic Drug Monitoring has been used for the management of epilepsy, cardiac arrhythmias, asthma and depression. This review provides an update, particularly for the newer clinical applications, and how therapeutic Drug Monitoring (including use of analytical and interpretation tools) can improve clinical outcomes. Improved Drug assay methodologies and a greater understanding of pharmacokinetic and pharmacodynamic mechanisms has allowed the use of therapeutic Drug Monitoring for immunosuppressant Drugs in organ transplant recipients, antiretroviral agents for HIV/AIDS and antimetabolite Drugs for leukaemia. In addition, new computer software to analyse Drug concentrations in complex populations is being developed and introduced into routine clinical applications to allow increasingly patient-specific assay interpretation. Therapeutic Drug Monitoring assists in improving clinical success rates and minimizing toxicity. The use of therapeutic Drug Monitoring is therefore likely to become more widespread as new modalities are adopted.
-
International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive Drug Monitoring.
Therapeutic drug monitoring, 2002Co-Authors: David W. Holt, Victo W Armstrong, Raymond G Morris, Kimberly L Napoli, Andrea Griesmacher, Leslie M. ShawAbstract:Issues surrounding the measurement and interpretation of immunosuppressive Drug concentrations have been summarized in a number of consensus documents, The Scientific Division of the International Federation of Clinical Chemistry has formed a working group in collaboration with the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. This paper sets out the goals of the working group in light of the developments that have occurred in the field of immunosuppressive Drug Monitoring since the publication of the last consensus documents.
David W. Holt - One of the best experts on this subject based on the ideXlab platform.
-
International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive Drug Monitoring.
Therapeutic drug monitoring, 2002Co-Authors: David W. Holt, Victo W Armstrong, Raymond G Morris, Kimberly L Napoli, Andrea Griesmacher, Leslie M. ShawAbstract:Issues surrounding the measurement and interpretation of immunosuppressive Drug concentrations have been summarized in a number of consensus documents, The Scientific Division of the International Federation of Clinical Chemistry has formed a working group in collaboration with the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. This paper sets out the goals of the working group in light of the developments that have occurred in the field of immunosuppressive Drug Monitoring since the publication of the last consensus documents.
-
Current opinions on therapeutic Drug Monitoring of immunosuppressive Drugs.
Clinical Therapeutics, 1999Co-Authors: Leslie M. Shaw, David W. Holt, Paul Keown, Raman Venkataramanan, Randall W. YatscoffAbstract:The pharmacokinetics of the immunosuppressive Drugs cyclosporine, tacrolimus, mycophenolate mofetil (MMF), and sirolimus are complex and unpredictable. A narrow therapeutic index unique to each patient, as well as variable absorption, distribution, and elimination, are characteristics of these Drugs. Therapeutic Drug Monitoring plays a key role in helping clinicians maintain blood and plasma levels of immunosuppressive Drugs within their respective therapeutic ranges. Variation in concentrations outside the narrow therapeutic ranges can result in adverse clinical outcomes. Therapeutic Drug Monitoring ensures that concentrations are not too high or too low, thereby reducing the risks of toxicity or rejection, respectively. Therapeutic Monitoring of immunosuppressive Drugs has been based on several choices of assay and biologic fluid (ie, whole blood, plasma) appropriate for a particular Drug. High-performance liquid chromatography (HPLC) remains the gold standard among assay methods used to monitor immunosuppressive Drugs. Although HPLC is the assay of choice for cyclosporine, newer monoclonal assays are suitable as well for routine Monitoring. HPLC is also widely used for therapeutic Drug Monitoring of mycophenolic acid, the active metabolite of MMF, and an immunoassay (used in European centers) has been developed. Therapeutic Drug Monitoring of tacrolimus has been improved with the recent development of assays with greater sensitivity and specificity for tacrolimus than those previously available. No commercial assays are currently available for the therapeutic Monitoring of sirolimus. It is also important to identify a specific pharmacokinetic parameter for each individual Drug, whether it is trough or area under the concentration-time curve, that may be most useful as a tool for optimal therapeutic Drug Monitoring in clinical practice. With an increased understanding of the pharmacokinetics of immunosuppressive Drugs, therapeutic Drug Monitoring guidelines will be more clearly defined to ensure the safe and effective management of transplant recipients.
Victo W Armstrong - One of the best experts on this subject based on the ideXlab platform.
-
international federation of clinical chemistry international association of therapeutic Drug Monitoring and clinical toxicology working group on immunosuppressive Drug Monitoring
Therapeutic Drug Monitoring, 2002Co-Authors: David W Hol, Victo W Armstrong, Andrea Griesmache, Raymond G Morris, Kimberly L Napoli, Leslie M. ShawAbstract:Issues surrounding the measurement and interpretation of immunosuppressive Drug concentrations have been summarized in a number of consensus documents, The Scientific Division of the International Federation of Clinical Chemistry has formed a working group in collaboration with the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. This paper sets out the goals of the working group in light of the developments that have occurred in the field of immunosuppressive Drug Monitoring since the publication of the last consensus documents.
-
International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive Drug Monitoring.
Therapeutic drug monitoring, 2002Co-Authors: David W. Holt, Victo W Armstrong, Raymond G Morris, Kimberly L Napoli, Andrea Griesmacher, Leslie M. ShawAbstract:Issues surrounding the measurement and interpretation of immunosuppressive Drug concentrations have been summarized in a number of consensus documents, The Scientific Division of the International Federation of Clinical Chemistry has formed a working group in collaboration with the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. This paper sets out the goals of the working group in light of the developments that have occurred in the field of immunosuppressive Drug Monitoring since the publication of the last consensus documents.
Kimberly L Napoli - One of the best experts on this subject based on the ideXlab platform.
-
international federation of clinical chemistry international association of therapeutic Drug Monitoring and clinical toxicology working group on immunosuppressive Drug Monitoring
Therapeutic Drug Monitoring, 2002Co-Authors: David W Hol, Victo W Armstrong, Andrea Griesmache, Raymond G Morris, Kimberly L Napoli, Leslie M. ShawAbstract:Issues surrounding the measurement and interpretation of immunosuppressive Drug concentrations have been summarized in a number of consensus documents, The Scientific Division of the International Federation of Clinical Chemistry has formed a working group in collaboration with the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. This paper sets out the goals of the working group in light of the developments that have occurred in the field of immunosuppressive Drug Monitoring since the publication of the last consensus documents.
-
International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive Drug Monitoring.
Therapeutic drug monitoring, 2002Co-Authors: David W. Holt, Victo W Armstrong, Raymond G Morris, Kimberly L Napoli, Andrea Griesmacher, Leslie M. ShawAbstract:Issues surrounding the measurement and interpretation of immunosuppressive Drug concentrations have been summarized in a number of consensus documents, The Scientific Division of the International Federation of Clinical Chemistry has formed a working group in collaboration with the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. This paper sets out the goals of the working group in light of the developments that have occurred in the field of immunosuppressive Drug Monitoring since the publication of the last consensus documents.
